Assay Detail
Functional
CHEMBL1666136
Review assay metadata, readout intent, target linkage, and publication context from the same page.
Antiviral activity against HIV1 A018G infected in human PBMC assessed as inhibition of viral p24 antigen production after 7 to 10 days by ELISA
6
Total Activities
6
Compounds Tested
1
Activity Types
0
Assay Parameters
Assay Information
| Assay Type | Functional |
| Organism | Human immunodeficiency virus 1 |
| Confidence | 1 — Organism |
| Curated By | Autocuration |
Target
Human immunodeficiency virus 1 (CHEMBL378) ↗| Type | ORGANISM |
| Organism | Human immunodeficiency virus 1 |
Publication
The novel CXCR4 antagonist KRH-3955 is an orally bioavailable and extremely potent inhibitor of human immunodeficiency virus type 1 infection: comparative studies with AMD3100.
Activity Statistics
| Type | Count | Avg pChEMBL | Best pChEMBL |
|---|---|---|---|
| EC50 | 6 | 6.82 | 8.89 |
Compounds Tested
| Compound | Name | Phase | Activities | Best pChEMBL |
|---|---|---|---|---|
| CHEMBL2062277 | — | — | 1 | 8.89 |
| CHEMBL18442 | PLERIXAFOR | 4.0 | 1 | 7.50 |
| CHEMBL129 | ZIDOVUDINE | 4.0 | 1 | 4.06 |
| CHEMBL518924 | MAVORIXAFOR | 4.0 | 1 | - |
| CHEMBL82301 | VICRIVIROC | 3.0 | 1 | - |
| CHEMBL114 | SAQUINAVIR | 4.0 | 1 | - |
Activity Data
| Compound | Name | Type | Rel. | Value | Units | pChEMBL |
|---|---|---|---|---|---|---|
| CHEMBL2062277 | — | EC50 | = | 1.3 | nM | 8.89 |
| CHEMBL18442 | PLERIXAFOR | EC50 | = | 32.0 | nM | 7.50 |
| CHEMBL129 | ZIDOVUDINE | EC50 | = | 87000.0 | nM | 4.06 |
| CHEMBL518924 | MAVORIXAFOR | EC50 | - | — | - | |
| CHEMBL82301 | VICRIVIROC | EC50 | - | — | - | |
| CHEMBL114 | SAQUINAVIR | EC50 | - | — | - |